Cannabis In Science & Health

ONE HEMP Study Reveals Safe CBD Upper Intake Limits – A Milestone for the Industry

ONE HEMP Study Reveals Safe CBD Upper Intake Limits – A Milestone for the Industry

In a significant step forward for the CBD industry, a coalition of CBD companies, known collectively as ONE HEMP, has taken the initiative to provide clarity on safe CBD consumption. This coalition’s primary goal is to engage with Congress and the Food and Drug Administration (FDA) to establish regulatory standards for CBD products. Recently, they […]

ONE HEMP Study Reveals Safe CBD Upper Intake Limits – A Milestone for the Industry Read More »

Study Reveals Improved Quality of Life with Medical Marijuana Use

Study Reveals Improved Quality of Life with Medical Marijuana Use

Researchers from the University of West Attica in Greece have unveiled the positive impact of medical marijuana on patients’ quality of life. The study, published in the journal GeNeDis Neuroscientific Advances, sheds light on the tangible benefits of medical cannabis use for individuals with neurological disorders. The findings challenge stigmas surrounding cannabis and emphasize its

Study Reveals Improved Quality of Life with Medical Marijuana Use Read More »

Rising Cannabis and Substance Use Among Adults NIH Survey 2022

Rising Cannabis and Substance Use Among Adults: NIH Survey 2022

The 2022 Monitoring the Future survey by the National Institutes of Health (NIH) has unveiled a concerning trend: past-year and daily cannabis use among adults aged 19-30 has reached unprecedented levels. This survey sheds light on the evolving landscape of cannabis consumption and its impact on young adults. The survey’s findings are clear: cannabis use

Rising Cannabis and Substance Use Among Adults: NIH Survey 2022 Read More »

Florida's Hemp Industry Faces Uncertainty Over THC Limits

Florida’s Hemp Industry Faces Uncertainty Over THC Limits

Florida’s hemp industry experienced a mix of relief and apprehension when proposed limits on THC content in hemp-derived products were dropped by lawmakers earlier this year. However, the sponsors of the legislation have hinted at revisiting these limits during the 2024 legislative session, stirring concerns within the hemp sector. Colleen Burton, a Polk County Republican

Florida’s Hemp Industry Faces Uncertainty Over THC Limits Read More »

Enhancing Quality of Life New Study Shows Benefits of Medical Marijuana Use

Enhancing Quality of Life: New Study Shows Benefits of Medical Marijuana Use

In a groundbreaking study conducted at the University of West Attica in Greece, researchers have unveiled compelling evidence that medical marijuana use is closely linked to improved quality of life, spanning areas such as job performance, sleep, appetite, and energy levels. The study, published in the GeNeDis Neuroscientific Advances journal, sheds light on the positive

Enhancing Quality of Life: New Study Shows Benefits of Medical Marijuana Use Read More »

OK Cannabis Fees Dispute

Oklahoma’s Medical Cannabis Fees Challenged: A Battle for Balance

The Oklahoma medical cannabis industry is at a crossroads, as a legal challenge looms over recently passed legislation that increases licensing fees for businesses operating in the sector. Oklahoma Supreme Court Justice John Kane heard arguments from the plaintiffs, including Jed Green, founder of Oklahomans for Responsible Cannabis Action, and three cannabis companies, who claim

Oklahoma’s Medical Cannabis Fees Challenged: A Battle for Balance Read More »

New Hampshire Allows Reciprocity for Medical Cannabis Patients

New Hampshire Allows Reciprocity for Medical Cannabis Patients

New Hampshire has implemented a reciprocity policy, enabling medical cannabis patients from other U.S. states and Canada to access cannabis products within the state. Under this law, visiting patients with valid medical cannabis identification from another state or Canada can purchase medical cannabis from New Hampshire dispensaries up to three times per year. The reciprocity

New Hampshire Allows Reciprocity for Medical Cannabis Patients Read More »

Minnesota Adds IBS and OCD to Medical Cannabis Program, Effective August 1

Minnesota Adds IBS and OCD to Medical Cannabis Program, Effective August 1

The Minnesota Department of Health has expanded its medical cannabis program by including irritable bowel syndrome (IBS) and obsessive-compulsive disorder (OCD) as qualifying conditions. Starting from August 1, patients diagnosed with these conditions will have access to medical cannabis from authorized dispensaries. Minnesota Commissioner of Health, Dr. Brooke Cunningham, emphasized the importance of offering additional

Minnesota Adds IBS and OCD to Medical Cannabis Program, Effective August 1 Read More »

University of California, San Diego Receives $1.5 Million Gift to Study DMT Effects on the Brain

University of California, San Diego Receives $1.5 Million Gift to Study DMT Effects on the Brain

The University of California, San Diego (UC San Diego) has been granted a significant boost in its research efforts surrounding the effects of dimethyltryptamine (DMT) on the brain. Philanthropist Eugene Jhong has generously gifted $1.5 million to the UC San Diego Psychedelics and Health Research Initiative, facilitating in-depth studies on the properties and impact of

University of California, San Diego Receives $1.5 Million Gift to Study DMT Effects on the Brain Read More »

The U.S. Food and Drug Administration (FDA) has published its Draft Guidance for the research of psychedelic drugs, including psilocybin, LSD, and MDMA. This guidance outlines the regulatory requirements and unique challenges associated with studying the therapeutic potential of these substances. The FDA aims to ensure that clinical studies are designed appropriately to evaluate safety and effectiveness while considering the distinctive characteristics of psychedelic drugs. The FDA's Draft Guidance emphasizes that psychedelic drug development programs must adhere to the same regulations and evidentiary standards as other drug development programs. Compliance with the federal Food, Drug, and Cosmetics Act is essential, and non-clinical investigations should follow the guidelines outlined in the Nonclinical Safety Studies for Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Designing clinical studies for psychedelic drugs presents unique challenges due to their profound effects on perception and consciousness, which can last for several hours. Some programs incorporate psychological or behavioral interventions, and researchers hypothesize that these drugs can provide rapid-onset and long-term benefits with just a few doses. These distinctive characteristics must be carefully considered to ensure the interpretability of study results. The FDA acknowledges that most medical conditions being studied in psychedelic research programs are chronic in nature. The proposed regulations provide a framework for psychedelic therapy, which is currently legal in Oregon. If the FDA were to approve a drug currently classified as a Schedule I substance under the Controlled Substances Act, the assessment of abuse potential would assist in determining appropriate rescheduling actions. The FDA is welcoming public comments on the proposed rules until August 28. This opportunity allows stakeholders and interested parties to provide feedback and contribute to the ongoing development of regulations for psychedelic drug research. Public input plays a crucial role in shaping the future of this field and ensuring safe and effective use of psychedelic therapies. Stay up-to-date with the ever-changing landscape of cannabis. Subscribe to NECANN today for the latest updates.

FDA Releases Draft Guidance for Psychedelic Drug Research

The U.S. Food and Drug Administration (FDA) has published its Draft Guidance for the research of psychedelic drugs, including psilocybin, LSD, and MDMA. This guidance outlines the regulatory requirements and unique challenges associated with studying the therapeutic potential of these substances. The FDA aims to ensure that clinical studies are designed appropriately to evaluate safety

FDA Releases Draft Guidance for Psychedelic Drug Research Read More »